These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

532 related articles for article (PubMed ID: 8626362)

  • 21. The safety profile of paroxetine.
    Boyer WF; Blumhardt CL
    J Clin Psychiatry; 1992 Feb; 53 Suppl():61-6. PubMed ID: 1531828
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Other Antidepressants.
    Schwasinger-Schmidt TE; Macaluso M
    Handb Exp Pharmacol; 2019; 250():325-355. PubMed ID: 30194544
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of pharmacologic treatments on the sleep of depressed patients.
    Sharpley AL; Cowen PJ
    Biol Psychiatry; 1995 Jan; 37(2):85-98. PubMed ID: 7718684
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An overview of paroxetine.
    Boyer WF; Feighner JP
    J Clin Psychiatry; 1992 Feb; 53 Suppl():3-6. PubMed ID: 1531819
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mirtazapine : A Review of its Pharmacology and Therapeutic Potential in the Management of Major Depression.
    Davis R; Wilde MI
    CNS Drugs; 1996 May; 5(5):389-402. PubMed ID: 26071050
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nefazodone: a new antidepressant.
    Ellingrod VL; Perry PJ
    Am J Health Syst Pharm; 1995 Dec; 52(24):2799-812. PubMed ID: 8748566
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug.
    Taylor DP; Carter RB; Eison AS; Mullins UL; Smith HL; Torrente JR; Wright RN; Yocca FD
    J Clin Psychiatry; 1995; 56 Suppl 6():3-11. PubMed ID: 7649970
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antidepressant efficacy in HIV-seropositive outpatients with major depressive disorder: an open trial of nefazodone.
    Elliott AJ; Russo J; Bergam K; Claypoole K; Uldall KK; Roy-Byrne PP
    J Clin Psychiatry; 1999 Apr; 60(4):226-31. PubMed ID: 10221282
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [New antidepressive drugs in comparison with classical tricyclics. Mechanism of action and clinical evaluation].
    Broocks A; Junghanns K; Thiel A; Gleiter CH; Bandelow B
    Fortschr Neurol Psychiatr; 2000 Jan; 68(1):17-24. PubMed ID: 10705571
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Black Book of Psychotropic Dosing and Monitoring.
    DeBattista C; Schatzberg AF
    Psychopharmacol Bull; 2024 Jul; 54(3):8-59. PubMed ID: 38993656
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression.
    Kent JM
    Lancet; 2000 Mar; 355(9207):911-8. PubMed ID: 10752718
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Methodologic approach to adverse events applied to bupropion clinical trials.
    Cato AE; Cook L; Starbuck R; Heatherington D
    J Clin Psychiatry; 1983 May; 44(5 Pt 2):187-90. PubMed ID: 6406455
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term treatment of depression with nefazodone.
    Anton SF; Robinson DS; Roberts DL; Kensler TT; English PA; Archibald DG
    Psychopharmacol Bull; 1994; 30(2):165-9. PubMed ID: 7831450
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comparison of nefazodone, imipramine, and placebo in patients with moderate to severe depression.
    Feighner JP; Pambakian R; Fowler RC; Boyer WF; D'Amico MF
    Psychopharmacol Bull; 1989; 25(2):219-21. PubMed ID: 2690165
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Venlafaxine and nefazodone, two pharmacologically distinct antidepressants.
    Augustin BG; Cold JA; Jann MW
    Pharmacotherapy; 1997; 17(3):511-30. PubMed ID: 9165554
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression.
    Fawcett J; Barkin RL
    J Affect Disord; 1998 Dec; 51(3):267-85. PubMed ID: 10333982
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Extended antidepressant maintenance and discontinuation syndromes.
    Maixner SM; Greden JF
    Depress Anxiety; 1998; 8 Suppl 1():43-53. PubMed ID: 9809213
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel serotonergic mechanisms and clinical experience with nefazodone.
    Fontaine R
    Clin Neuropharmacol; 1993; 16 Suppl 3():S45-50. PubMed ID: 8131154
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimizing antidepressant treatment: efficacy and tolerability.
    Deakin B; Dursun S
    Int Clin Psychopharmacol; 2002 Jun; 17 Suppl 1():S13-24. PubMed ID: 12369607
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion.
    Horst WD; Preskorn SH
    J Affect Disord; 1998 Dec; 51(3):237-54. PubMed ID: 10333980
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.